Associated Papers
Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider.
Roncato R et al.
British Journal of Clinical Pharmacology, 2026
Pharmacogenomic Calling From Whole-Exome Sequencing in the Taiwanese Population-A Real-World Experience.
Lin HH et al.
Molecular Genetics & Genomic Medicine, 2026
A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer.
Boige V et al.
Journal of the National Cancer Institute, 2025
Potential clinical relevance of rare dihydropyrimidine dehydrogenase genetic variants identified using whole-exome NextGen sequencing in cancer patients with severe fluoropyrimidine toxicity.
Cui E et al.
Cancer Chemotherapy and Pharmacology, 2025
Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects.
Bernsen EC et al.
Clinical Pharmacology and Therapeutics, 2025
Impact of Upfront DPYD Genotyping on Fluoropyrimidine Adjuvant Therapy in Colorectal Cancer: A Real-World Data.
Saarenheimo J et al.
Clinical Colorectal Cancer, 2025
DPYD Genotyping, Fluoropyrimidine Dosage and Toxicity: An Umbrella Review of Systematic Reviews.
Otero-Torres S et al.
Pharmaceuticals (basel, Switzerland), 2025
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature.
Liguori C et al.
Cancer Chemotherapy and Pharmacology, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution.
D'Amato M et al.
World Journal of Gastrointestinal Oncology, 2025
Comprehensive pharmacogenomics profiling of the Serbian population.
Jelovac M et al.
Frontiers in Pharmacology, 2025
Clinical impact of pharmacogenomics in pediatric care: insights extracted from clinical exome sequencing.
Maggo S et al.
Frontiers in Genetics, 2025
Pharmacogenomic landscape of the Thai population from genome sequencing of 949 individuals.
Piriyapongsa J et al.
Scientific Reports, 2024
Pharmacogenetic DPYD allele variant frequencies: A comprehensive analysis across an ancestrally diverse Iranian population.
Sarhangi N et al.
Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2024
Pharmacogenetic analysis of structural variation in the 1000 genomes project using whole genome sequences.
Sherman CA et al.
Scientific Reports, 2024
DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2024
Characterization of Reference Materials for DPYD: A GeT-RM Collaborative Project.
Gaedigk A et al.
The Journal of Molecular Diagnostics : Jmd, 2024
Dihydropyrimidine Dehydrogenase Polymorphism c.2194G>A Screening Is a Useful Tool for Decreasing Gastrointestinal and Hematological Adverse Drug Reaction Risk in Fluoropyrimidine-Treated Patients.
Ardizzone A et al.
Current Issues in Molecular Biology, 2024
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD.
Knikman JE et al.
Genome Medicine, 2024
MIR27A Gene Polymorphism Modifies the Effect of Common DPYD Gene Variants on Severe Toxicity in Patients with Gastrointestinal Tumors Treated with Fluoropyrimidine-Based Anticancer Therapy.
Ikonnikova A et al.
International Journal of Molecular Sciences, 2024
DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review.
Chan TH et al.
British Journal of Cancer, 2024
Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study.
Díaz-Villamarín X et al.
Pharmaceutics, 2024
Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (DPYD).
Ambrodji A et al.
International Journal of Molecular Sciences, 2024
Fluoropyrimidine Toxicities and DPYD Genotyping: A Clinical Case.
Peixoto M et al.
Cureus, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
A systematic review and meta-analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer.
Lingaratnam S et al.
Clinical and Translational Science, 2024
Contradiction in Star-Allele Nomenclature of Pharmacogenes between Common Haplotypes and Rare Variants.
Ahn SH et al.
Genes, 2024
Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity.
Larrue R et al.
The Pharmacogenomics Journal, 2024
Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing.
Turner AJ et al.
Clinical and Translational Science, 2024
Improving single nucleotide polymorphisms genotyping accuracy for dihydropyrimidine dehydrogenase testing in pharmacogenetics.
Montella A et al.
Exploration of Targeted Anti-tumor Therapy, 2024
Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobank.
Li B et al.
American Journal of Human Genetics, 2023
Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?
Arrivé C et al.
British Journal of Clinical Pharmacology, 2023
Precision fluoropyrimidines dosing in a compound heterozygous variant carrier of the DPYD gene: a case report.
Baiardi G et al.
Cancer Chemotherapy and Pharmacology, 2023
Profiling of pharmacogenomic variants in CYP2D6 and DPYD in indigenous Arab breast cancer patients.
Alsulaiman A et al.
Pharmacogenomics, 2023
A Comprehensive Analysis of 21 Actionable Pharmacogenes in the Spanish Population: From Genetic Characterisation to Clinical Impact.
Nunez-Torres R et al.
Pharmaceutics, 2023